Are the Patients Ready for the Change?: An Empirical Study to Evaluate the Impact of Change in Formulation of Buprenorphine-Naloxone on Prescription Pattern, Treatment Adherence, and Patient Satisfaction

References

• Balhara, Y. P. (2014). A chart review based comparative study of retention rates for two dispensing regimens for buprenorphine for subjects with opioid dependence at a tertiary care substance use disorder treatment center. Journal of Opioid Management, 10(3), 200–206. doi:10.5055/jom.2014.0208.
   PubMedGoogle Scholar
• Damon, W., Small, W., Anderson, S., Maher, L., Wood, E., Kerr, T., & McNeil, R. (2017). ‘Crisis’ and ‘everyday’ initiators: A qualitative study of coercion and agency in the context of methadone maintenance treatment initiation. Drug and Alcohol Review, 36(2), 253–260. doi:10.1111/dar.12411
   PubMed Web of Science ®Google Scholar
• Daulouède, J.-P., Caer, Y., Galland, P., Villeger, P., Brunelle, E., Bachellier, J., … Courty, P. (2010). Preference for buprenorphine/naloxone and buprenorphine among patients receiving buprenorphine maintenance therapy in France: A prospective, multicenter study. Journal of Substance Abuse Treatment, 38(1), 83–89. doi:10.1016/j.jsat.2009.07.002.
   PubMed Web of Science ®Google Scholar
• Dayal, P., & Balhara, Y. P. S. (2017). A naturalistic study of predictors of retention in treatment among emerging adults entering first buprenorphine maintenance treatment for opioid use disorders. Journal of Substance Abuse Treatment, 80, 1–5. doi:10.1016/j.jsat.2017.06.004.
   PubMed Web of Science ®Google Scholar
• Faasse, K., Cundy, T., Gamble, G., & Petrie, K. J. (2013). The effect of an apparent change to a branded or generic medication on drug effectiveness and side effects. Psychosomatic Medicine, 75(1), 90–96. doi:10.1097/PSY.0b013e3182738826.
   PubMed Web of Science ®Google Scholar
• Fischer, A., Jonsson, M., & Hjelmstrom, P. (2015). Pharmaceutical and pharmacokinetic characterization of a novel sublingual buprenorphine/naloxone tablet formulation in healthy volunteers. Drug Development and Industrial Pharmacy, 41(1), 79–84. doi:10.3109/03639045.2013.846365.
   PubMed Web of Science ®Google Scholar
• Greene, J. A., & Kesselheim, A. S. (2011). Why do the same drugs look different? Pills, trade dress, and public health. New England Journal of Medicine, 365(1), 83–89. doi:10.1056/NEJMhle1101722.
   PubMed Web of Science ®Google Scholar
• Greer, A. M., Hu, S., Amlani, A., Moreheart, S., Sampson, O., & Buxton, J. A. (2016). Patient perspectives of methadone formulation change in British Columbia, Canada: Outcomes of a provincial survey. Substance Abuse Treatment, Prevention, and Policy, 11(1), 3. doi:10.1186/s13011-016-0048-3.
   PubMedGoogle Scholar
• Gunderson, E. W., & Sumner, M. (2016). Efficacy of buprenorphine/naloxone rapidly dissolving sublingual tablets (BNX-RDT) after switching from BNX sublingual film. Journal of Addiction Medicine, 10(2), 124–130. doi:10.1097/ADM.0000000000000201.
   PubMed Web of Science ®Google Scholar
• Kesselheim, A. S., Bykov, K., Avorn, J., Tong, A., Doherty, M., & Choudhry, N. K. (2014). Burden of changes in pill appearance for patients receiving generic cardiovascular medications after myocardial infarction: Cohort and nested case-control studies. Annals of Internal Medicine, 161(2), 96–103. doi:10.7326/M13-2381.
   PubMed Web of Science ®Google Scholar
• Kesselheim, A. S., Misono, A. S., Shrank, W. H., Greene, J. A., Doherty, M., Avorn, J., & Choudhry, N. K. (2013). Variations in pill appearance of antiepileptic drugs and the risk of nonadherence. JAMA Internal Medicine, 173(3), 202–208. doi:10.1001/2013.jamainternmed.997.
   PubMed Web of Science ®Google Scholar
• Lumbreras, B., & Lopez-Pintor, E. (2017). Impact of changes in pill appearance in the adherence to angiotensin receptor blockers and in the blood pressure levels: A retrospective cohort study. BMJ Open, 7(3), e012586. doi:10.1136/bmjopen-2016-012586.
   PubMed Web of Science ®Google Scholar
• Magura, S., Lee, J. D., Hershberger, J., Joseph, H., Marsch, L., Shropshire, C., & Rosenblum, A. (2009). Buprenorphine and methadone maintenance in jail and post-release: A randomized clinical trial. Drug Alcohol Depend, 99(1–3), 222–230. doi:10.1016/j.drugalcdep.2008.08.006.
   PubMed Web of Science ®Google Scholar
• Moerman, D. E. (2006). The meaning response: Thinking about placebos. Pain Practice: The Official Journal of World Institute of Pain, 6(4), 233–236.
   PubMedGoogle Scholar
• Montesano, F., Zaccone, D., Battaglia, E., Genco, F., & Mellace, V. (2010). Therapeutic switch to buprenorphine/naloxone from buprenorphine alone. Clinical Experience in an Italian Addiction Centre: Clin Drug Investigation, 30 (Suppl 1), 13–19.
   PubMedGoogle Scholar
• Neumann, A. M., Blondell, R. D., Azadfard, M., Nathan, G., & Homish, G. G. (2013). Primary care patient characteristics associated with completion of 6-month buprenorphine treatment. Addictive Behaviors, 38(11), 2724–2728. doi:10.1016/j.addbeh.2013.07.007.
   PubMed Web of Science ®Google Scholar
• Pinto, H., Maskrey, V., Swift, L., Rumball, D., Wagle, A., & Holland, R. (2010). The SUMMIT trial: A field comparison of buprenorphine versus methadone maintenance treatment. Journal of Substance Abuse Treatment, 39(4), 340–352. doi:10.1016/j.jsat.2010.07.009.
   PubMed Web of Science ®Google Scholar
• Schuckit, M. A. (2016). Treatment of opioid-use disorders. New England Journal of Medicine, 375(16), 1596–1597. doi:10.1056/NEJMc1610830
   PubMedGoogle Scholar
• Silver, J. S., & Shaffer, H. J. (1996). Change intolerance to shifts in methadone formulation: A preliminary investigation. Journal of Substance Abuse Treatment, 13(4), 331–339. doi:10.1016/S0740-5472(96)00099-2.
   PubMed Web of Science ®Google Scholar
• Stimolo, C., Favero, V. D., Zecchinato, G., Buson, R., Cusin, D., Pellachin, P., & Simonetto, P. (2010). Safety and tolerability of the switch from buprenorphine to buprenorphine/naloxone in an Italian addiction treatment centre. Clinical Drug Investigation, 30 (Suppl 1), 27–31. doi:10.2165/11536030-000000000-00000.
   PubMedGoogle Scholar
• Teruya, C., Schwartz, R. P., Mitchell, S. G., Hasson, A. L., Thomas, C., Buoncristiani, S. H., … Ling, W. (2014). Patient perspectives on buprenorphine/naloxone: A qualitative study of retention during the starting treatment with agonist replacement therapies (START) study. Journal of Psychoactive Drugs, 46(5), 412–426. doi:10.1080/02791072.2014.921743
   PubMed Web of Science ®Google Scholar
• Tkacz, J., Severt, J., Cacciola, J., & Ruetsch, C. (2012). Compliance with buprenorphine medication-assisted treatment and relapse to opioid use. The American Journal on Addictions, 21(1), 55–62. doi:10.1111/j.1521-0391.2011.00186.x
   PubMed Web of Science ®Google Scholar
• Tkacz, J., Volpicelli, J., Un, H., & Ruetsch, C. (2014). Relationship between buprenorphine adherence and health service utilization and costs among opioid dependent patients. Journal of Substance Abuse Treatment, 46(4), 456–462. doi:10.1016/j.jsat.2013.10.014.
   PubMed Web of Science ®Google Scholar